Linden Thomas Advisory Services LLC Sells 407 Shares of Lantheus Holdings, Inc. $LNTH

Linden Thomas Advisory Services LLC reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,162 shares of the medical equipment provider’s stock after selling 407 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Lantheus were worth $1,814,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Westfield Capital Management Co. LP raised its holdings in Lantheus by 2.2% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock worth $155,101,000 after purchasing an additional 34,052 shares during the period. Reinhart Partners LLC. raised its holdings in Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after purchasing an additional 197,719 shares during the period. Dimensional Fund Advisors LP raised its holdings in Lantheus by 2.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after purchasing an additional 31,454 shares during the period. Swedbank AB raised its holdings in Lantheus by 11.0% in the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after purchasing an additional 121,500 shares during the period. Finally, TD Asset Management Inc raised its holdings in Lantheus by 1,028.0% in the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock worth $66,623,000 after purchasing an additional 622,100 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have commented on LNTH. TD Cowen decreased their price target on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. Truist Financial set a $63.00 price target on Lantheus and gave the company a “hold” rating in a report on Monday, August 11th. B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. William Blair reissued a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $74.50.

Lantheus Trading Down 0.8%

Shares of NASDAQ LNTH opened at $56.06 on Friday. The business’s 50 day moving average is $54.14 and its two-hundred day moving average is $71.83. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $118.21. The stock has a market capitalization of $3.81 billion, a P/E ratio of 14.91 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $92.51 million for the quarter. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.